Author: Sihua Zhao1, Rongna Lian2, Ruinian Zhang2, Fanghong Wang3, Hao Chen4, Run Wan5
Affiliation:
1 Lanzhou University First Hospital Nursing Department (School of Nursing Lanzhou University).
2 The First Clinical Medical College of Lanzhou University.
3 General Surgery Department of The First Hospital of Lanzhou University.
4 Lanzhou University Second Hospital Oncology Center.
5 Lanzhou University Second Hospital Nursing Department, Lanzhou, China.
Conference/Journal: Medicine (Baltimore)
Date published: 2021 Apr 2
Other:
Volume ID: 100 , Issue ID: 13 , Pages: e25380 , Special Notes: doi: 10.1097/MD.0000000000025380. , Word Count: 210
Background:
Taijiquan, as a supplementary and alternative method, has attracted more and more attention in the treatment of breast cancer. But up to now, no systematic review has been performed to evaluate the efficacy of Taijiquan in the treatment of breast cancer. In this study, Cochrane systematic review method will be used to evaluate the effect of Taijiquan in the rehabilitation process of breast cancer patients after treatment.
Methods:
PubMed, Embase. com, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, and SinoMed will be searched to identify relevant studies up to May 31, 2021. We will include randomized controlled trials (RCTs) of the application of Taijiquan in post-treatment breast cancer patients. We will use the Cochrane bias risk assessment tool to assess the quality of included RCTs. We will use Stata 13.0 to perform pairwise meta-analyses using the inverse variance method. Subgroup analyses and sensitivity analyses will be conducted to investigate the sources of heterogeneity.
Results:
The results of this study will be published in a peer-reviewed journal.
Conclusion:
This study will comprehensively evaluate the efficacy of Taijiquan in the rehabilitation treatment of breast cancer. The results of this study will provide high-quality evidence to support clinical practice and guidelines development.
PMID: 33787643 DOI: 10.1097/MD.0000000000025380